Focusing on the Frontier of Laboratory Medicine, Building the Future of Clinical Diagnosis and Treatment Together - 2025 Guangci Laboratory Medicine Innovation and Development Conference Held in Shanghai

From June 5 to 8, 2025, Guangci Laboratory Medicine Innovation and Development Conference was successfully held in Qingsong City, Shanghai. With the theme of “Innovation, Leadership, Development”, the conference was jointly organized by six authoritative institutions, including the School of Medical Technology of Shanghai Jiao Tong University School of Medicine, Shanghai University of Medicine & Health Sciences, and Ruijin Hospital of Shanghai Jiao Tong University School of Medicine, and brought together nearly 100 domestic and international renowned experts and scholars to discuss the innovation and development in the field of laboratory medicine.

Focusing on clinical applications, new breakthroughs in Hematological Testing

As an important part of the conference, the Clinical Blood and Body Fluid Sub-forum centered on the in-depth discussion of commonly used clinical examination items, and many experts shared the latest research results and practical applications.

Combined with the research results of the team, Prof. Wei Xu  from the First Hospital of Jilin University introduced “Urine Cytology and TPS Report” in detail, and deeply analyzed the key role of this technology in the diagnosis of urological diseases. She pointed out that accurate urine cytology combined with standardized TPS report can provide more valuable diagnostic basis for clinics and help early diagnosis of diseases.

Wei Xu - The First Hospital of Jilin University

Urine Cytology and TPS Report.

National Center for Clinical Laboratories Professor Mingting Peng in the “industry standards to help the development of high-quality clinical testing,” the theme of the report, a detailed explanation of the background of the development of testing-related industry standards and the effectiveness of the implementation of the correct application of the industry standards for medical laboratories to provide authoritative guidance. This initiative will further promote the standardized development of laboratory medicine.

Mingting Peng - National Center for Clinical Laboratories

Industry Standards for High Quality Development of Clinical Testing

Professor Mianyang Li of the General Hospital of the Chinese People's Liberation Army, in his report “Problems and Measures of Prophylactic Morphological Tests”, systematically elaborates the core value of providing diagnostic basis for infectious diseases and hematologic diseases through cell morphology characterization.

Mianyang Li - PLA General Hospital First Medical Center

Problems and Measures in Prophylactic Morphologic Testing.

Prof. Wenrong Xu from Medical Frontier Research Institute of Jiangsu University shared the latest results of “Research on Small Cell Extracellular Vesicle Molecular Markers and Tumor Diagnosis and Treatment”, introducing its biological properties and potential value in the diagnosis of tumors and other diseases, which provides a new technical path for the development of clinical testing.

Wenrong Xu - Jiangsu University Medical Frontier Research Institute

A Study of Molecular Markers of Small Extracellular Vesicles and Tumor Diagnosis and Treatment.

Prof. Simba Kanwal from Chulalongkorn University, Thailand, presented “Bridging the Basic Research in Drug Discovery with the Development of Clinical Laboratory Medicine”, emphasizing the close connection between basic research in drug discovery and the development of clinical laboratory medicine, and provided new ideas for the development of translational medicine.

Simab Kanwal 

《Bridging the Basic Research in Drug Discovery with the Development of Clinical Laboratory Medicine》

Professor Huachun Weng of Shanghai Medical College of Health Sciences, in his report “Diagnostic Biomarkers for Kidney Diseases”, systematically introduced the current status of the application of existing markers in the diagnosis and treatment of kidney diseases and proposed the research direction of new markers, emphasizing the significance of high specificity markers for the diagnosis of kidney diseases.

Huachun Weng - Shanghai Medical College of Health Sciences

Diagnostic Biomarkers for Kidney Disease.

Prof. Danfeng Dong from Ruijin Hospital of Shanghai Jiao Tong University shared the valuable experience of Ruijin Hospital in “Intelligent Laboratory Construction and Future Development”, showing the broad application prospects of artificial intelligence, big data and other new technologies in laboratory medicine.

Danfeng Dong - Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

The Construction and Future Development of Smart Laboratories

Shanghai Clinical Laboratory Center Professor Xiaobo Hu in the “Shanghai Mutual Recognition of Test Results Progress” report stressed that the mutual recognition of test results for the optimization of medical resource allocation, reduce the burden on patients and improve medical efficiency is of great significance.

Xiaobo Hu - Shanghai Clinical Laboratory Center

Progress of Mutual Recognition of Test Results in Shanghai

Multi-dimensional discussion to build a new landscape of laboratory medicine

The conference set up five sub-forums on clinical blood and body fluids, microbiology, immunology, molecular diagnostics and emerging technologies, discipline construction and laboratory management, which demonstrated the latest development of laboratory medicine in an all-round way.

The Immunology Forum focuses on the application of novel biomarkers in disease diagnosis, covering hot topics such as early warning of acute myocardial infarction, autoimmune disease detection, and the application of artificial intelligence, which points out the direction of the development of immunoassay technology.

New Technology Forum of Molecular Diagnostics and Testing focused on tumor molecular diagnostics, nanotechnology, mass spectrometry and other cutting-edge fields, explored the role of eccDNA in tumors, Mycoplasma pneumoniae drug resistance detection and other clinical applications, and showed the great potential of molecular diagnostic technology.

The Clinical Microbiology Forum provides in-depth discussions on key issues such as Clostridium difficile infections, diagnosis of bloodstream infections, prevention and control of drug-resistant bacteria, and provides new strategies for precise diagnosis and treatment of infectious diseases. 

The Discipline Construction and Laboratory Management Forum focuses on key topics such as the application of AI in medical testing, laboratory quality control, and integration of industry and education, which provides valuable experience for the construction of the discipline of laboratory medicine and the cultivation of talents.

Enabling technological innovation to promote the high-quality development of laboratory medicine

Since its inception in 2022, the Guangci Congress of Innovative Development of Laboratory Medicine has attracted widespread attention in the medical community and become an important platform for professionals in the field of laboratory medicine to exchange ideas, share experiences and discuss cooperation. The successful organization of this conference fully demonstrates the vigorous development of China's testing medicine field, and brings new breakthroughs and progress to testing medicine by gathering the wisdom of top experts from home and abroad to discuss the application of cutting-edge technologies.

As an important participant in this conference, Sunbio presented its newly released UG2500 coagulation analyzer at the conference. The device integrates the dual advantages of optical and mechanical methods for coagulation detection, and also has the function of platelet aggregation, which can realize the integrated detection of phase I and phase II hemostasis. Equipped with a five-wavelength light source and an independent HIL monitoring channel, the device can intelligently switch detection methods, and integrates advanced functions such as APTT auto-correction, auto-factor parallel analysis, switching on/off by appointment, closed-cap puncture, and on-line refrigeration of reagents, which provides a comprehensive solution for clinical coagulation testing.

Shanghai Sunbio is dedicated to providing high-quality coagulation testing solutions for medical institutions at all levels, and has established a comprehensive product system from reagents to instruments to fully meet the testing needs of hospitals at different levels. The participation in the Guangci Medical Innovation and Development Conference fully reflects the company's mission to promote the development of testing and fulfill its social responsibilities. In the future, the company will continue to help the high-quality development of China's testing industry with innovative technology, and contribute more to the promotion of the construction of a healthy China and the maintenance of people's health.

About Shanghai Sunbio

Founded in 2001, Shanghai SunBio technology Co., Ltd. specializes in thrombosis and hemostasis diagnostics, and is a mainstream supplier of thrombosis and hemostasis total solutions in the world. With the concept of “Creating products for life”, the company is committed to the research, development, production and sales of thrombosis and hemostasis diagnostic reagents, medical instruments and medical consumables.

The company strictly adheres to the quality management system and has passed ISO9001 and ISO13485 dual international quality system certification. Our core products have independent intellectual property rights, with more than 100 patents. Meanwhile, we have actively participated in the formulation of national industry standards for PT, APTT, TT, FIB, D-Dimer, anti-Xa and coagulation analyzer, promoting the standardization of coagulation testing technology. The company has been awarded a number of honors and qualifications, such as Ministry of Industry and Information Technology Specialized, National High-tech Enterprises, Shanghai Science and Technology Small Giant Enterprises, Shanghai 100 Intelligent Factories, and so on.

In the future, Shanghai Sun Bio will continue to plough into the field of thrombosis and hemostasis diagnostics, adhere to scientific and technological innovation to drive product upgrading, and continue to provide professional coagulation diagnostic solutions for global customers, and help the healthy development of the global healthcare industry.